Screening for Hypertensive Pregnancy Complications through Maternal Serum PAPP-A 5th and 10th Percentiles during the 11-14 Weeks Gestational Age Interval

Voicu Dascau,Cristina Onel,Maria Puschita,Gheorghe Furau,Luminita Pilat

doi:10.37358/rc.20.2.7924

Abstract

The aim of our study was to assess the predictive values for hypertensive complications of pregnancy of the multiples of median (MoM) of serum pregnancy associated plasma protein A (PAPP-A), measured in 128 pregnant patients between 11 and 14 weeks gestational age. The 5th and the 10th percentile for MoM PAPP-A were 0.27 and 0.33, respectively. The detection rate for pregnancy induced hypertension, mild preeclampsia, severe preeclampsia, all preeclampsia and all hypertensive complications was 0%, 9.09%, 0%, 7.69%, and 6.25% for MoM PAPP-A below the 5th percentile (for a false positive rate of 5%), and 33.33%, 9.09%, 0%, 7.69%, and 12.5% for MoM PAPP-A below the 10th percentile (for a false positive rate of 10%), respectively. The specificity ranged from 89.57% to 95.73%, the positive predictive value from 0% to 16.67%, and the negative predictive value from 87.70% to 98.36%.

Highlights

The aim of our study was to assess the predictive values for hypertensive complications of pregnancy of the multiples of median (MoM) of serum pregnancy associated plasma protein A (PAPP-A), measured in 128 pregnant patients between 11 and 14 weeks gestational age
Maternal serum concentrations are related to subsequent fetal growth and it can be used as a diagnostic test for adverse pregnancy outcomes, including intrauterine growth restriction, premature birth, preeclampsia, and stillbirth [1]
The plasmatic concentrations of PAPP-A are altered in pregnant patients who will develop preeclampsia (PE), the predictive value being high especially for the preterm type 2,3

Summary

Experimental part Materials and methods

The study included 128 pregnant patients with gestational ages between 11 weeks and 13 weeks+6 days, who were examined by ultrasound, including uterine artery Doppler, and who had the plasmatic concentration of PAPP-A determined. Plasmatic PAPP-A was determined with the ELISA Sunrise device, Tecan, Switzerland, and Pregnancy Associated Plasma Protein A reactant, MBS026323, MyBioSource, Inc., USA

Results and discussions

Family history of DM

PE Total hypertension

Conclusions